Key Takeaways AbbVie settled with generic drugmakers, extending Rinvoq exclusivity until April 2037.Rinvoq sales jumped 48% to $3.75B, now 13% of AbbVie's total revenue.New indications may add $2B to Rinvoq's peak sales, reinforcing AbbVie's growth outlook.Shares of AbbVie (ABBV) rose over 4% to a record high on Thursday after the company announced that it had settled patent litigation with all generic manufacturers who had sought the FDA’s approval for generic versions of its blockbuster immunology drug, R ...